BHC Q2 2026 Earnings Call Summary

Bausch Health (BHC) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $2.852 billion, a 13% increase year-over-year; 11% organic growth.
Adjusted EBITDA: $1.075 billion, up 28% year-over-year, with a 59% adjusted EBITDA margin (up 530 basis points).
Adjusted Cash Flow from Operations: $637 million, a 44% increase year-over-year.
BHC Excluding Bausch + Lomb:
- Revenue: $1.458 billion, a 16% increase.
- Adjusted EBITDA: $865 million, up 28%.
- Adjusted Cash Flow from Operations: $471 million, up 32%.

2. Strategic Updates and Business Highlights

Salix Segment: Revenue grew 21% to $758 million, primarily driven by Xifaxan demand and favorable pricing.
International Segment: Revenue of $305 million, with LATAM up 16% and EMEA achieving 14 consecutive quarters of organic growth.
Solta Medical Segment: Revenue increased 38% to $176 million, with a 69% rise in segment profit, driven by strong performance in China.
Debt Management: Net debt reduced to $13.7 billion, down $434 million in Q2, aided by low legacy litigation and restructuring payments.
Operational Efficiency: Continued focus on optimizing resources and tightening G&A infrastructure.

3. Forward Guidance and Outlook

Full-Year Guidance Raised:
- Revenue: Expected between $5.35 billion and $5.50 billion.
- Adjusted EBITDA: Expected between $3.025 billion and $3.100 billion.
- Adjusted Cash Flow from Operations: Expected between $1.4 billion and $1.475 billion.
2027 Guidance: Adjusted EBITDA expected at $2.7 billion, factoring in new CMS rebates starting January 1, 2027.

4. Bad News, Challenges, or Points of Concern

Second Half Growth Expectations: Anticipated lower growth rates for revenue and adjusted EBITDA due to:
- A $150 million headwind from gross-to-net accrual changes.
- Loss of exclusivity for Aplenzin, expected to impact revenue by $50 million.
- Gradual erosion of Medicaid and 340B revenue, estimated at $75 million.
Generic Competition: Concerns regarding the future impact of generic competition on Xifaxan and overall profitability.
Market Uncertainty: Ongoing uncertainty in the broader environment could affect future performance.

5. Notable Q&A Insights

Business Development Focus: Management expressed interest in expanding into adjacent therapeutic areas, particularly in U.S. Pharma, with a disciplined approach to capital allocation.
Bausch + Lomb Asset Monetization: Discussions on timing and strategy for realizing Bausch + Lomb's value, with aggressive financial targets set for 2027.
Impact of Tariffs on Generics: Potential tariffs on generics announced by the administration are not expected to have a significant immediate impact, as they won't take effect until mid-2028.

Overall, Bausch Health reported strong financial performance in Q2 2026, with significant growth across its segments and improved cash flow generation. However, the company faces challenges in the second half of the year, particularly related to pricing pressures and competition, which could impact future growth. The management remains optimistic about strategic initiatives and business development opportunities moving forward.

BHC — Bausch Health Companies Inc.